Tagrisso Funding Journey Shows UK’s Revamped Cancer Drugs Fund Is No Soft Touch
Executive Summary
AstraZeneca’s Tagrisso is the first product accepted for use on the National Health Service through the reformed Cancer Drugs Fund, but it took two tries to persuade HTA body NICE it should be funded at all. NICE examined Merck Sharp & Dohme’s Keytruda and it’s not impressed. The Pink Sheet takes a closer look at the new dynamics illustrated by these lung cancer treatments’ review.
You may also be interested in...
UK NICE Says Yes To Vizimpro & Libtayo But Rejects Tagrisso
Pfizer and AstraZeneca were seeking National Health Service funding for the same indication for their respective lung cancer drugs. With "responsible pricing" after an initial rejection, Pfizer prevailed.
Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
Positive Tagrisso Data Boost AstraZeneca's Lung Cancer Ambitions
Latest data from AstraZeneca's Tagrisso will help the company to convert the lung cancer drug's conditional approvals to full approvals, and boost reimbursement negotiations.